The $70M upfront provides immediate cash runway and validates navenibart's commercial potential. Monitor Phase 3 data readouts and milestone triggers (regulatory filings) for further upside. The partnership reduces European commercial risk.
Price Chart
Executive Summary
BioCryst entered a European licensing agreement for navenibart (HAE) with Neopharmed Gentili, receiving $70M upfront and up to $275M in milestones plus tiered royalties (18-30%). The deal strengthens the balance sheet and provides non-dilutive capital while retaining significant upside. Phase 3 remains on track for US filing by end-2027.
Key Facts
- $70 million upfront payment
- Up to $275 million in future regulatory and sales milestone payments
- Tiered royalties on net sales ranging from 18% to 30%
- Neopharmed Gentili gains exclusive European commercialization rights
- Navenibart Phase 3 program on track for US regulatory filing by end of 2027
- Builds on prior 2025 agreement for ORLADEYO European business sale
Financial Impact
Upfront $70M cash infusion, potential total deal value up to $345M including milestones, plus ongoing royalties (18-30%)
Risk Factors
- Clinical trial failure or regulatory delays for navenibart
- Milestone and royalty payments depend on approval and commercial success
- Partner execution risk in European market
- Potential dilution if future capital needs exceed expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002960 |
| Exhibit: exh_991.htm | 0001171843-26-002960 |
| Document: 0001171843-26-002960-index-headers.html | 0001171843-26-002960 |
| Document: 0001171843-26-002960-index.html | 0001171843-26-002960 |
| Document: 0001171843-26-002960.txt | 0001171843-26-002960 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.14 (−10.25%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.14 (−14.76%) |
Jun 12, 2026 15w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.14 (−10.15%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.14 (−6.44%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.14 (−6.86%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.14 (−15.21%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.14 (−7.81%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.14 (−11.52%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.14 (−8.95%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.14 (−13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access